UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Stringent cessation criterion results in better durability of lamivudine treatment: a prospective clinical study in hepatitis B e antigen-positive chronic hepatitis B patients

Journal of viral hepatitis, 2010-04, Vol.17 (4), p.298-304

2010

Volltextzugriff (PDF)

Comparison of three galenic forms of lamivudine in young West African children living with Human Immunodeficiency Virus

Antiviral therapy, 2021-11, Vol.26 (6-8), p.134-140

2021

Volltextzugriff (PDF)

The impact of once-nightly versus twice-daily dosing and baseline beliefs about HAART on adherence to efavirenz-based HAART over 48 weeks: the NOCTE study

Journal of acquired immune deficiency syndromes (1999), 2010-03, Vol.53 (3), p.369-377

2010

Volltextzugriff (PDF)

Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection

The New England journal of medicine, 2013-11, Vol.369 (19), p.1807-1818

2013

Volltextzugriff (PDF)

Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial

The Lancet (British edition), 2017-09, Vol.390 (10101), p.1499-1510

2017

Volltextzugriff (PDF)

Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial

Clinical infectious diseases, 2023-02, Vol.76 (4), p.720-729

2023

Volltextzugriff (PDF)

Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials

Journal of acquired immune deficiency syndromes (1999), 2020-03, Vol.83 (3), p.310-318

2020

Volltextzugriff (PDF)

Cost Effectiveness of Entecavir versus Lamivudine with Adefovir Salvage in HBeAg-Positive Chronic Hepatitis B

PharmacoEconomics, 2007-01, Vol.25 (11), p.963-977

2007

Volltextzugriff (PDF)

Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial

Journal of acquired immune deficiency syndromes (1999), 2019-08, Vol.81 (4), p.463-472

2019

Volltextzugriff (PDF)

Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized Trial

Clinical infectious diseases, 2018-05, Vol.66 (11), p.1794-1797

2018

Volltextzugriff (PDF)

Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study

The Lancet infectious diseases, 2016-05, Vol.16 (5), p.565-575

2016

Volltextzugriff (PDF)

Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy - naive adults with HIV-1 infection

AIDS (London), 2022-01, Vol.36 (1), p.39-48

2022

Volltextzugriff (PDF)

ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)-infected Participants With HIV-1 RNA <500000 Copies/mL

Clinical infectious diseases, 2018-05, Vol.66 (11), p.1689-1697

2018

Volltextzugriff (PDF)

Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients

International journal of antimicrobial agents, 2019-12, Vol.54 (6), p.728-734

2019

Volltextzugriff (PDF)

Rapid Initiation of Antiretroviral Therapy With Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide Versus Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate in HIV-Positive Men Who Have Sex With Men in China: Week 48 Results of the Multicenter, Randomized Clinical Trial

Clinical infectious diseases, 2024-07, Vol.79 (1), p.169-176

2024

Volltextzugriff (PDF)

Mechanistic Insight into Antiretroviral Potency of 2′-Deoxy-2′-β-fluoro-4′-azidocytidine (FNC) with a Long-Lasting Effect on HIV‑1 Prevention

Journal of medicinal chemistry, 2020-08, Vol.63 (15), p.8554-8566

2020

Volltextzugriff (PDF)

Twenty-Five Years of Lamivudine: Current and Future Use for the Treatment of HIV-1 Infection

Journal of acquired immune deficiency syndromes (1999), 2018-06, Vol.78 (2), p.125-135

2018

Volltextzugriff (PDF)

A novel formulation enabled transformation of 3-HIV drugs tenofovir-lamivudine-dolutegravir from short-acting to long-acting all-in-one injectable

AIDS (London), 2023-11, Vol.37 (14), p.2131-2136

2023

Volltextzugriff (PDF)

Immunomodulatory Mechanism of Acyclic Nucleoside Phosphates in Treatment of Hepatitis B Virus Infection

Hepatology (Baltimore, Md.), 2020-05, Vol.71 (5), p.1533-1545

2020

Volltextzugriff (PDF)

Five Years With Dolutegravir Plus Lamivudine as a Switch Strategy: Much More Than a Positive Finding

Journal of acquired immune deficiency syndromes (1999), 2021-11, Vol.88 (3), p.234-237

2021

Volltextzugriff (PDF)

2-Year GLOBE Trial Results: Telbivudine Is Superior to Lamivudine in Patients With Chronic Hepatitis B

Gastroenterology (New York, N.Y. 1943), 2009-02, Vol.136 (2), p.486-495

2009

Volltextzugriff (PDF)

Antiviral Drugs for Viruses Other Than Human Immunodeficiency Virus

Mayo Clinic proceedings, 2011-10, Vol.86 (10), p.1009-1026

Razonable, Raymund R., MD

2011

Volltextzugriff (PDF)

1 – 25 von 5.250

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(4.401)
Mit Volltextzugriff
(3.862)

Publikationsform

Sprache

15 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Humans
(5.188)
Lamivudine - Therapeutic Use
(4.448)
Science & Technology
(3.911)
Life Sciences & Biomedicine
(3.791)
Male
(2.914)
Female
(2.775)
Adult
(2.690)
Antiviral Agents - Therapeutic Use
(2.284)
Infectious Diseases
(2.006)
Middle Aged
(1.978)
Hiv Infections - Drug Therapy
(1.923)
Hepatitis B, Chronic - Drug Therapy
(1.787)
Lamivudine
(1.688)
Anti-Hiv Agents - Therapeutic Use
(1.656)
Biological And Medical Sciences
(1.607)
Medical Sciences
(1.579)
Reverse Transcriptase Inhibitors - Therapeutic Use
(1.492)
Drug Therapy, Combination
(1.437)
Treatment Outcome
(1.326)
Hepatitis B Virus
(1.146)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

MEDLINE
(5.243)
Journals@Ovid Complete
(2.628)
EZB Electronic Journals Library
(2.570)
IngentaConnect Journals
(2.111)
IngentaConnect Journals
(1.126)
Publisher or Other Site
(1.054)
Wiley Online Library Journals Frontfile Complete
(923)
Wiley Online Library Full Collection 2018
(824)
Elsevier ScienceDirect Journals Complete
(707)
SpringerLink Journals - AutoHoldings
(395)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(339)
Oxford University Press Journals Current
(305)
Oxford Journals 2020 Medicine
(296)
SAGE Complete
(259)
Jstor Complete Legacy
(221)
Taylor & Francis Journals
(190)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(189)
Taylor & Francis
(184)
Taylor & Francis Online
(157)
Nexis Uni
(81)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Aids
(260)
Antiviral Therapy
(190)
Zhonghua Gan Zang Bing Za Zhi
(138)
Journal Of Acquired Immune Deficiency Syndromes
(126)
Journal Of Hepatology
(124)
Hepatology
(113)
Plos One
(102)
Journal Of Medical Virology
(100)
The Journal Of Infectious Diseases
(99)
Journal Of Viral Hepatitis
(96)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(8)

Menü

Weitere Dienste

Einstellungen

Stringent cessation criterion results in better durability of lamivudine treatment: a prospective clinical study in hepatitis B e antigen-positive chronic hepatitis B patients

Comparison of three galenic forms of lamivudine in young West African children living with Human Immunodeficiency Virus

The impact of once-nightly versus twice-daily dosing and baseline beliefs about HAART on adherence to efavirenz-based HAART over 48 weeks: the NOCTE study

Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection

Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial

Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial

Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials

Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study

Cost Effectiveness of Entecavir versus Lamivudine with Adefovir Salvage in HBeAg-Positive Chronic Hepatitis B

Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial

Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized Trial

Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study

Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy - naive adults with HIV-1 infection

Reverse-Transcriptase Inhibitors in the Aicardi–Goutières Syndrome

ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)-infected Participants With HIV-1 RNA <500000 Copies/mL

Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients

Rapid Initiation of Antiretroviral Therapy With Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide Versus Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate in HIV-Positive Men Who Have Sex With Men in China: Week 48 Results of the Multicenter, Randomized Clinical Trial

Mechanistic Insight into Antiretroviral Potency of 2′-Deoxy-2′-β-fluoro-4′-azidocytidine (FNC) with a Long-Lasting Effect on HIV‑1 Prevention

Twenty-Five Years of Lamivudine: Current and Future Use for the Treatment of HIV-1 Infection

A novel formulation enabled transformation of 3-HIV drugs tenofovir-lamivudine-dolutegravir from short-acting to long-acting all-in-one injectable

Immunomodulatory Mechanism of Acyclic Nucleoside Phosphates in Treatment of Hepatitis B Virus Infection

Five Years With Dolutegravir Plus Lamivudine as a Switch Strategy: Much More Than a Positive Finding

2-Year GLOBE Trial Results: Telbivudine Is Superior to Lamivudine in Patients With Chronic Hepatitis B

Antiviral Drugs for Viruses Other Than Human Immunodeficiency Virus

Suchergebnisse filtern